GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 98 7. Provide details related to waste management by the entity, in the following format: Your company collects back post-consumer plastic waste from the market on Pan India basis and disposes it in an environmentally sound manner every year as an Extended Producer Responsibility (EPR) obligation: • FY 2021-22: 1,652.75 MT Plastic Waste collected and disposed as per EPR obligation. • FY 2020-21: 2,070.52 MT Plastic Waste collected and disposed as per EPR obligation. 1. For Nashik plant Parameter Generated Nature of disposal FY 2021-22 FY 2020-21 Total Waste generated (in metric tonnes) E-waste 0.56 0.36 Safe disposal through government authorized vendors Bio-medical waste 2.21 2.24 Safe disposal through government authorized vendors Battery waste 1.39 – Safe disposal through government authorized vendors Other Hazardous waste. 219.00 317.17 Incinerated as per regulations Total 223.16 319.77 For corporate office Parameter FY 2021-22 FY 2020-21 Nature of recovery Total Waste generated (in metric tonnes) E-waste 0 5.27 Recycled through government authorized recyclers Other Non-hazardous waste generated 2.59 NA Recycled through government authorized recyclers 8. Briefly describe the waste management practices adopted in your establishments. Describe the strategy adopted by your company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices adopted to manage such wastes. • Your company collects the waste generated from its own operations. The waste is then segregated and handed over to authorised waste handlers for recycling and incineration, as appropriate. Since 2010, your company has been able to reduce waste to landfill by over 78%. • Several waste management practices are deployed at our Nashik site to reduce waste from ointments and tablets. Approximately 9,000 kgs of waste has been reduced from 2020 7 to 2021 8 . • The Kaizen program at the Nashik site offers employees the opportunity to brainstorm and find solutions to reduce the use of single-use plastics within the premises. Some of the interventions which have been undertaken include the usage of cloth shoe covers instead of plastic shoe covers in the laboratories and swapping plastic milk pouches with milk cans in the cafeteria. 9. If the entity has operations/offices in/around ecologically sensitive areas (such as national parks, wildlife sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where environmental approvals/clearances are required: The manufacturing site in Nashik is not located in a notified ecologically sensitive region. The Ambad site is a region under the purview of the Maharashtra Industrial Development Corporation. Further, all the environmental permits and clearances required by law and the statutes of the Maharashtra Pollution Control Board and the Central Pollution Control Board are obtained and renewed periodically. 10. Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in the current financial year: As per the notification of the Ministry of Environment, Forests and Climate Change in India, an Environmental Impact Assessment is supposed to be carried out for industries which have an adverse impact on the environment. The pharmaceutical sector is not notified as an industry which requires an EIA pre-clearance by the MOEFCC. Additionally, your company’s Business Responsibility and Sustainability Report 7 and 8 as per Calendar Year